Despite the analysts’ downbeat assessment, Oliver Sartor, M.D., Director of Radiopharmaceutical Trials and Professor of ...
Novartis is making two investments in new radiopharmaceutical manufacturing sites in the US. The Swiss pharmaceutical giant will open a third US radioligand plant in Carlsbad, California, to serve the ...
BAMF Health in Grand Rapids offers the Pluvicto treatment. It targets only prostate cancer cells with radiation.
The trial compares Eli Lilly’s lutetium zadavotide guraxetan with Astellas’s Xtandi or Janssen’s Zytiga for mPRPC.
The company is building a new facility in California, its third U.S.-based radioligand therapy production site, and expanding ...
Just two years into its existence, radioisotope producer PanTera has drawn 93 million euros ($102.5 million) in an ...
Radioligand therapies (RLTs) have received prominent attention from major pharmaceutical companies in treating prostate ...
(ITM), a leading radiopharmaceutical biotech company, today announced its participation in two upcoming industry investor ...
Bayer is targeting a broader use of Nubeqa in metastatic hormone-sensitive prostate (mHSPC) cancer with a combination free of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback